Reading SVRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SVRA free→Reading SVRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SVRA free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and earnings quality cannot be assessed as the company was unprofitable over the past year. Management's recent track record has been fairly steady, and it has a capital-friendly stance. Risk is elevated, and the sector backdrop is a headwind, which may impact performance compared with sector peers. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $5.33. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.83x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
10 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.14 → $-0.15 (-3.0% / 30d). 0 raised, 1 cut, 5 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$234.
How much price usually moves either way.
On a bad day, this stock has moved -$462.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,199.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: A rebound in healthcare growth could help Savara's performance.
Confirms:Healthcare sector revenue growth speeds up back toward over 10%.
Disproves:Healthcare sector revenue growth keeps slowing below current levels.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for SVRA yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amendment of 2024 Omnibus Incentive Plan On June 4, 2026, the stockholders of Savara Inc. (“Savara”) approved an amendment to the Savara Inc. 2024 Omnibus Incentive Plan (the “2024 Plan”), to increase the number of shares of common stock authorized for issuance thereunder by 18,900,000 shares (the “2024 Plan Amendment”). The 2024 Plan Amendment was…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
SVRA Savara, Inc. | — | — | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 77 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Savara plans to relocate its headquarters to Yardley, PA, with the lease commencing on July 1, 2026.
Newly stated in 2026-Q1. Savara plans to relocate its headquarters to Yardley, PA, with the lease commencing on July 1, 2026. This strategic move is aimed at supporting future growth, but financial impact is yet to be seen.
“Savara entered into a lease agreement to relocate its headquarters to Yardley, PA.”
Savara approved an amendment to increase shares for the 2024 Omnibus Incentive Plan by 18,900,000 shares.
Newly stated in 2026-Q2. Savara increased the number of shares for the 2024 Omnibus Incentive Plan by 18,900,000 shares. This move is intended to enhance talent retention and incentivization, but its effectiveness will depend on future talent metrics.
“Savara approved an amendment to increase shares for the 2024 Omnibus Incentive Plan by 18,900,000 shares.”
Savara amended its Loan Agreement to allow borrowing up to $105 million in term loans.
Newly stated in 2026-Q1. Savara amended its Loan Agreement to increase borrowing capacity to $105 million. This capital allocation strategy aims to support operational needs, but the impact on financials remains to be assessed.
“Savara amended its Loan Agreement to allow borrowing up to $105 million in term loans.”
Entry into a Material Definitive Agreement. On March 10, 2026, Savara Inc. (the “Company”) entered into an Agreement of Lease (the “Lease”) with ML7 Yardley Partners, LP (“Landlord”), pursuant to which the Company will lease approximately 10,795 square feet of office space located at 19 W. College Avenue, Suite 200, Yardley, PA 19067. The Company plans to relocate its headquarters to this location. The term of the Lease commences on July 1, 2026 and continues until December 1, 2031 (the “Term…
Entry into a Material Definitive Agreement. On January 26, 2026, Savara Inc. (the “Company”) entered into a First Amendment (the “First Amendment”) to the Loan and Security Agreement, dated March 26, 2025 (the “Loan Agreement”), with the lenders party thereto (the “Lenders”) and Hercules Capital, Inc., as administrative agent and collateral agent. As amended, the Loan Agreement provides for the Company to borrow up to an aggregate of $105 million of term loans. The First Amendment reset the t…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under Item 1.01, “Entry into a Material Definitive Agreement,” is incorporated herein by reference. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 27, 2026 SAVARA INC. a Delaware corporation By:…
Entry into a Material Definitive Agreement. On October 29, 2025, Savara Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell (i) an aggregate of 23,809,524 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and (ii) pre-funded…